The findings of DCA demonstrated that SMURF2 exhibited a favorable overall benefit and possessed the ability to forecast the overall survival of individuals diagnosed with oral cancer, both in the short and long term (Fig. 8D–F). The gene discussed is SMURF2; the disease is lip and oral cavity carcinoma.